{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-059242","form_type":"8-K","ticker":null,"cik":"0000316253","company_name":"ENZO BIOCHEM INC","filed_at":"2023-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.241854+00:00","generated_at":"2026-06-13T04:34:28.200949+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Enzo Biochem closes clinical lab sale to Labcorp for $113.25M cash; exits lab business","bullets":["Asset sale of Enzo Clinical Labs to Labcorp closed on July 24, 2023 for aggregate cash consideration of $113.25 million.","Enzo will cease all clinical laboratory operations and focus on its life sciences business.","Transaction was previously announced on March 16, 2023 and amended on July 3, 2023.","Jefferies and McDermott Will & Emery advised Enzo; Evercore and Hogan Lovells advised Labcorp."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-059242","json":"https://secwatch.observer/filing/0001213900-23-059242.json","markdown":"https://secwatch.observer/filing/0001213900-23-059242.md","text":"https://secwatch.observer/filing/0001213900-23-059242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/316253/000121390023059242/0001213900-23-059242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/316253/000121390023059242/ea182199-8k_enzobiochem.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:34:28.200949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f85bdb8d7c5066da1993cf2205a648fa99daa468","claim":"ENZO BIOCHEM INC completed a disposition involving Laboratory Corporation of America Holdings for $113.25 million in cash (closed 2023-07-24).","evidence_excerpt":"On July 24, 2023 (the “Closing Date”), pursuant to the terms of the Asset Purchase Agreement, as amended (the “Purchase Agreement”), by and among Enzo Biochem, Inc., a New York corporation (the “Company”), Enzo Clinical Labs, Inc., a New York corporation, and Laboratory Corporation of America Holdings, a Delaware corporation, the Company closed the sale of certain assets and assignment of certain liabilities of the Company’s clinical laboratory business (the “Asset Sale”) for $113.25 million in cash (the “Purchase Price”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390023059242/0001213900-23-059242-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Laboratory Corporation of America Holdings"},{"label":"Consideration","value":"$113.25 million in cash"},{"label":"Closing","value":"2023-07-24"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}